Table 2.
Patient characteristics by change in RAASi dose following an HK episode
| US | Japan | |||||
|---|---|---|---|---|---|---|
| Maintained or up-titrated | Discontinued | Down-titrated | Maintained or up-titrated | Discontinued | Down-titrated | |
| Characteristic | N = 5922 | N = 3223 | N = 650 | N = 3023 | N = 1591 | N = 303 |
| aExcluded from the denominator for non-missing data | ||||||
| Age at index, years | ||||||
| Mean (SD) | 69.5 (12.3) | 70.6 (12.4) | 68.7 (12.3) | 75.5 (11.6) | 78.1 (11.2) | 76.6 (11.1) |
| Median (IQR) | 70 (61–79) | 72 (62–80) | 69 (60–78) | 77 (70–84) | 79.0 (73–86) | 78 (72–85) |
| Male, n (%) | 3135 (52.9) | 1669 (51.8) | 343 (52.8) | 1977 (65.4) | 950 (59.7) | 199 (65.7) |
| History of HK, n (%) | 2137 (36.1) | 1229 (38.1) | 224 (34.5) | 473 (15.6) | 257 (16.2) | 42 (13.9) |
| HK severity at index, n (%) | ||||||
| > 5.0–5.49 | 1941 (51.9) | 956 (44.0) | 212 (47.3) | 118 (34.6) | 32 (25.8) | < 11 pts |
| 5.5–5.99 | 1239 (33.1) | 757 (34.8) | 138 (30.8) | 166 (48.7) | 42 (33.9) | 14 (56.0) |
| ≥ 6 | 561 (15.0) | 462 (21.2) | 98 (21.9) | 57 (16.7) | 50 (40.3) | < 11 pts |
| Missinga | 2181 (36.8) | 1048 (32.5) | 202 (31.1) | 2682 (88.7) | 1467 (92.2) | 278 (91.7) |
| Diabetes at baseline, n (%) | 3848 (65.0) | 2137 (66.3) | 441 (67.8) | 1245 (41.2) | 699 (43.9) | 132 (43.6) |
| CKD stage at baseline by diagnosis code or by eGFR, n (%) | ||||||
| 3 or 4 | 4586 (77.4) | 2460 (76.3) | 460 (70.8) | 793 (26.2) | 323 (20.3) | 63 (20.8) |
| 3 | 3601 (60.8) | 1829 (56.7) | 357 (54.9) | 299 (9.9) | 115 (7.2) | 20 (6.6) |
| 4 | 985 (16.6) | 631 (19.6) | 103 (15.8) | 494 (16.3) | 208 (13.1) | 43 (14.2) |
| HF at baseline, n (%) | 3048 (51.5) | 1966 (61.0) | 430 (66.2) | 2617 (86.6) | 1460 (91.8) | 278 (91.7) |
| RAASi at baseline, n (%) | ||||||
| ACEi | 3475 (58.7) | 1922 (59.6) | 413 (63.5) | 658 (21.8) | 356 (22.4) | 72 (23.8) |
| ARB | 1895 (32.0) | 1051 (32.6) | 198 (30.5) | 2167 (71.7) | 1021 (64.2) | 199 (65.7) |
| ARNi | 283 (4.8) | 190 (5.9) | 43 (6.6) | 18 (0.6) | 14 (0.9) | < 11 pts |
| MRA | 1208 (20.4) | 1062 (33.0) | 210 (32.3) | 730 (24.1) | 823 (51.7) | 169 (55.8) |
ACEi Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, ARNi Angiotensin receptor-neprilysin inhibitor, CKD Chronic kidney disease, eGFR Estimated glomerular filtration rate, HF Heart failure, HK Hyperkalemia, IQR Interquartile range, MRA Mineralocorticoid receptor antagonist, pts Patients, RAASi Renin-angiotensin-aldosterone system inhibitor, SD Standard deviation